fluoxetine has been researched along with Obesity in 118 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 9.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain." | 9.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "The effects of fluoxetine on food intake, body weight, and mood of obese individuals was examined in a 16-week inpatient/outpatient study." | 9.09 | Fluoxetine-maintained obese humans: effect on food intake and body weight. ( Comer, SD; Fischman, MW; Foltin, RW; Haney, M; Ward, AS, 1999) |
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 9.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| "Fluoxetine is effective, well tolerated and relatively safe in the short-term treatment of obesity in the Taiwanese population when added to a low calorie diet." | 9.08 | Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. ( Chian, CY; Huang, CC; Lin, JD, 1998) |
| "Fluoxetine improves insulin-mediated glucose disposal in obese patients with NIDDM independently of weight loss." | 9.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| "Our study aims at assessing the efficacy and safety of fluoxetine as compared with placebo in the treatment of obesity using a double-blind crossover design." | 9.08 | Comparison of fluoxetine and placebo in the treatment of obesity. ( Barredo-Acedo, F; Escobar-Jiménez, F; Fernández-Soto, ML; González-Jiménez, A; Luna del Castillo, JD, 1995) |
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 9.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "The effect of fluoxetine on body weight and spontaneous food choice was studied in twenty-three healthy, non-depressed, obese females on an outpatient basis." | 9.07 | Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. ( Koppeschaar, HP; Meinders, AE; Op de Kamp, I; Pijl, H; Veldhuis, HD; Willekens, FL, 1991) |
| "Fluoxetine hydrochloride (Lovan, Eli Lilly and Company, Indianapolis, Indiana, USA), a specific serotonin uptake inhibitor, was compared with placebo in 458 obese outpatients in a 52-week double-blind randomized ten-site trial to study its effect on weight reduction." | 9.07 | Fluoxetine: a randomized clinical trial in the treatment of obesity. ( Enas, GG; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1994) |
| " To demonstrate the use of this methodology, we applied the criteria in an analysis of eight randomized, double-blind controlled trials comparing fluoxetine (n = 522) with placebo (n = 504) for weight loss." | 9.07 | Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. ( Atkinson, RL; Goldstein, DJ; Roback, PJ; Sayler, ME, 1994) |
| " Fluoxetine, an inhibitor of serotonin reuptake, decreases food intake in animals and is associated with weight loss in depressed and otherwise healthy obese patients." | 9.06 | Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). ( Byyny, RL; Dauer, AD; Enas, GG; Kirby, RW; Kreindler, TG; Levine, LR; Levy, B; Lucas, CP; McIlwain, HH; Thompson, WL, 1989) |
| "Fluoxetine is a highly specific serotonin reuptake inhibitor." | 7.77 | Clinical studies with fluoxetine in obesity. ( Wise, SD, 1992) |
| "Fluoxetine, a serotonin re-uptake inhibitor with antidepressive and appetite reduction effects, could improve insulin sensitivity." | 7.69 | [The effect of fluoxetine on insulin resistance in non diabetic obese patients]. ( Aguirre, C; Araya, V; Contreras, P; Depix, MS; Zura, ML, 1995) |
| "Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e." | 6.71 | Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005) |
| "Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients." | 6.68 | Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. ( Astrup, A; Bak, JF; Bjerre, U; Breum, L; Jacobsen, S, 1995) |
| "Obesity is a major health care concern because of its associated medical complications and increased mortality." | 6.68 | Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. ( Goldstein, DJ; Hamilton, SH; Rampey, AH; Roback, PJ; Sayler, ME; Tollefson, GD; Wilson, MG, 1995) |
| "Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss." | 6.67 | Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993) |
| "Fluoxetine is a specific inhibitor of serotonin re-uptake with very minimal affinity for serotonergic or other receptors." | 6.66 | Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. ( Bosomworth, J; Levine, LR; Rosenblatt, S, 1987) |
| "Hypogonadotropic hypogonadism is a major characteristic of patients with PWS, and it is speculated to be due to hypothalamic insufficiency." | 5.29 | Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. ( Clayton, AH; O'Donnell, T; Shaw, HA; Warnock, JK, 1995) |
| "Fluoxetine treatment of mice restricted to 3." | 5.28 | Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice. ( Dubuc, PU; Peterson, CM, 1990) |
| " The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated." | 5.27 | Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987) |
| "To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss." | 5.19 | A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014) |
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 5.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain." | 5.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 5.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| "The effects of fluoxetine on food intake, body weight, and mood of obese individuals was examined in a 16-week inpatient/outpatient study." | 5.09 | Fluoxetine-maintained obese humans: effect on food intake and body weight. ( Comer, SD; Fischman, MW; Foltin, RW; Haney, M; Ward, AS, 1999) |
| "Our study aims at assessing the efficacy and safety of fluoxetine as compared with placebo in the treatment of obesity using a double-blind crossover design." | 5.08 | Comparison of fluoxetine and placebo in the treatment of obesity. ( Barredo-Acedo, F; Escobar-Jiménez, F; Fernández-Soto, ML; González-Jiménez, A; Luna del Castillo, JD, 1995) |
| "We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking." | 5.08 | Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995) |
| "Fluoxetine improves insulin-mediated glucose disposal in obese patients with NIDDM independently of weight loss." | 5.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| " To demonstrate the use of this methodology, we applied the criteria in an analysis of eight randomized, double-blind controlled trials comparing fluoxetine (n = 522) with placebo (n = 504) for weight loss." | 5.07 | Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. ( Atkinson, RL; Goldstein, DJ; Roback, PJ; Sayler, ME, 1994) |
| "Fluoxetine, an inhibitor of serotonin re-uptake, has been shown to cause weight loss in humans and animals." | 5.07 | Fluoxetine treatment of the obese diabetic. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992) |
| "Fluoxetine hydrochloride (Lovan, Eli Lilly and Company, Indianapolis, Indiana, USA), a specific serotonin uptake inhibitor, was compared with placebo in 458 obese outpatients in a 52-week double-blind randomized ten-site trial to study its effect on weight reduction." | 5.07 | Fluoxetine: a randomized clinical trial in the treatment of obesity. ( Enas, GG; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1994) |
| "Suicidality data from 11 double-blind controlled trials in the United States Investigational New Drug fluoxetine obesity clinical trial data base (3819 randomized outpatients) were reviewed." | 5.07 | Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. ( Beasley, CM; Goldstein, DJ; Masica, DN; Potvin, JH; Rampey, AH, 1993) |
| "To determine whether fluoxetine is effective in the long-term treatment of obesity and whether it is particularly useful in the treatment of obese binge-eaters, the authors randomly assigned 45 obese subjects (22 with binge-eating problems and 23 without binge-eating) to fluoxetine (60 mg/day) or placebo in a 52-week double-blind trial." | 5.06 | A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. ( Ewing, L; Gooding, W; Kern, E; Marcus, MD; McDermott, M; Wing, RR, 1990) |
| " Fluoxetine, an inhibitor of serotonin reuptake, decreases food intake in animals and is associated with weight loss in depressed and otherwise healthy obese patients." | 5.06 | Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). ( Byyny, RL; Dauer, AD; Enas, GG; Kirby, RW; Kreindler, TG; Levine, LR; Levy, B; Lucas, CP; McIlwain, HH; Thompson, WL, 1989) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks." | 4.82 | Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005) |
| " Survival analysis was performed using Cox proportional hazards regression models and visualized using Kaplan Meier survival curves, with the following covariates-sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension." | 4.31 | Effect of statins on the age of onset of age-related macular degeneration. ( Chiang, JN; Corradetti, G; Ganesh, D; Halperin, E; Sadda, SR; Zaitlen, N, 2023) |
| " We aimed to investigate the relationships among body weight, body mass index (BMI=kg/m(2)), change in a depression rating scale, and change in a functional scale with fluoxetine treatment for hospitalized patients with major depressive disorder (MDD)." | 3.80 | Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. ( Chen, CC; Lin, CH; McIntyre, RS; Wong, J, 2014) |
| "Fluoxetine is a highly specific serotonin reuptake inhibitor." | 3.77 | Clinical studies with fluoxetine in obesity. ( Wise, SD, 1992) |
| "Chronic fluoxetine administration in obese Zucker rats generated a reduction in body weight gain, food intake, adipocyte size, fat mass, and body protein." | 3.71 | Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus. ( Abecia, LC; Casis, L; Echevarría, E; Gutiérrez, A; Macarulla, MT; Portillo, MP; Rodríguez, VM; Saracíbar, G, 2002) |
| " They also had mature onset obesity characterized by a dramatic 80-150% increase in body weight, increased linear growth, and elevated serum levels of leptin, insulin, glucose, and cholesterol." | 3.71 | Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. ( Bates, B; Fan, G; Fekete, C; Jaenisch, R; Kelly, J; Kuehn, R; Lechan, RM; Rios, M, 2001) |
| " To illustrate an application of this method, we used data from 1,026 patients completing at least 6 months of double-blind therapy in clinical trials comparing fluoxetine (N=522) with placebo (N=504) for weight loss." | 3.69 | Baseline predictors of success when comparing two treatments. ( Goldstein, DJ; Rampey, AH; Roback, PJ; Wilson, MG, 1994) |
| "Serotonin reuptake inhibitors, such as fluoxetine, fenfluramine, and dexfenfluramine, are frequently used to treat obesity, depression, and bulimia." | 3.69 | Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study. ( Boyd, LD; Dwyer, JT; Papas, A, 1997) |
| "Fluoxetine, a serotonin re-uptake inhibitor with antidepressive and appetite reduction effects, could improve insulin sensitivity." | 3.69 | [The effect of fluoxetine on insulin resistance in non diabetic obese patients]. ( Aguirre, C; Araya, V; Contreras, P; Depix, MS; Zura, ML, 1995) |
| "Sertraline has been studied less extensively, and there have been a few studies concerning SSRIs that report follow-up data at more than 12 weeks of follow-up." | 2.73 | A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. ( Brustolin, A; Campisi, S; Fassino, S; Lavagnino, L; Leombruni, P; Pierò, A, 2008) |
| "Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e." | 2.71 | Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005) |
| " FL did not affect thermic response to oral glucose neither after acute nor chronic administration (p=NS for all groups studied)." | 2.69 | Metabolic effects of fluoxetine in obese menopausal women. ( Bertolini, M; Bondi, M; Del Rio, G; Menozzi, R; Venneri, MG, 2000) |
| "Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients." | 2.68 | Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. ( Astrup, A; Bak, JF; Bjerre, U; Breum, L; Jacobsen, S, 1995) |
| "Obesity is a major health care concern because of its associated medical complications and increased mortality." | 2.68 | Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. ( Goldstein, DJ; Hamilton, SH; Rampey, AH; Roback, PJ; Sayler, ME; Tollefson, GD; Wilson, MG, 1995) |
| "Fluoxetine treatment produced a significant weight loss of 1." | 2.68 | Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. ( Blundell, JE; Hill, AJ; Lawton, CL; Wales, JK, 1995) |
| "Weight reduction is essential in the management of most non-insulin-dependent diabetics, but this therapeutical goal is difficult to obtain." | 2.68 | Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. ( Daubresse, JC; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1996) |
| "After treatment, weight loss (on average) was observed in both groups: -2." | 2.67 | The effect of fluoxetine on body weight, body composition and visceral fat accumulation. ( Koppeschaar, HP; Seidell, JC; Smits, P; Visser, M, 1993) |
| "Fluoxetine is an antidepressant drug with weight reducing properties." | 2.67 | An assessment of the thermogenic effects of fluoxetine in obese subjects. ( Andrews, JF; Murphy, CM; Stinson, JC; Tomkin, GH, 1992) |
| "Body weight was kept constant." | 2.67 | Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. ( Frölich, M; Krans, HM; Meinders, AE; Potter van Loon, BJ; Radder, JK; Zwinderman, AH, 1992) |
| "Fluoxetine is an inhibitor of serotonin re-uptake which has been found to produce weight loss in humans and animals." | 2.67 | A randomized double-blind clinical trial of fluoxetine in obese diabetics. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992) |
| "When nondiabetics and NIDDM were considered together, only the most insulin-resistant individuals demonstrated a decrease in ED50pgu (P less than 0." | 2.67 | Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. ( Frölich, M; Krans, HM; Meinders, AE; Potter van Loon, BJ; Radder, JK; Zwinderman, AH, 1992) |
| "Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved." | 2.67 | Fluoxetine therapy in obese diabetic and glucose intolerant patients. ( Daubresse, JC; Friedman, H; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1992) |
| "Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss." | 2.67 | Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993) |
| "Obesity is a major cause of increased morbidity and mortality among patients with PWS." | 2.44 | [Therapeutical approach of obesity in Prader-Willi Syndrome]. ( Almeida, MQ; Carvalho, DF; Cercato, C; Halpern, A; Mancini, MC, 2007) |
| "Obesity is associated with considerable morbidity and decreased life expectancy." | 2.41 | Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002) |
| "Because obesity is a risk factor for numerous medical disorders and excess mortality, it is imperative that effective treatments be developed." | 2.40 | Challenges in obesity management. ( Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS, 1998) |
| "A number of symptoms associated with eating disorders overlap those of depression and OCD, suggesting a theoretical and practical case for evaluating the SSRIs in the treatment of anorexia nervosa, bulimia nervosa, binge-eating disorder, and obesity." | 2.40 | The use of selective serotonin reuptake inhibitors in eating disorders. ( Mayer, LE; Walsh, BT, 1998) |
| "Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem." | 2.40 | The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997) |
| "Fluoxetine has a nonlinear pharmacokinetic profile." | 2.39 | Clinical pharmacokinetics of fluoxetine. ( Altamura, AC; Moro, AR; Percudani, M, 1994) |
| "The resultant weight loss is variable and there appears to be no way of predicting good responders, nor is there evidence that additional weight loss attributable to drug therapy is sustained once treatment is discontinued, although nonpharmacological strategies for preventing weight regain are worthy of exploration." | 2.38 | Appraisal of the clinical value of serotoninergic drugs. ( Hodge, J; Munro, JF; Scott, C, 1992) |
| " We aimed to characterise the prevalence and seriousness of adverse drug events (ADEs) related to anti-obesity medications and to identify predictors associated with increased risk of serious adverse events (SAE), thereby conveying evidence on drug safety." | 1.91 | A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication. ( Choi, CY; Choi, YJ; Kim, CU; Shin, S, 2023) |
| "Fluoxetine was the reference treatment option in the medication models." | 1.39 | Influence of body mass index on the choice of therapy for depression and follow-up care. ( Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E, 2013) |
| "Fluoxetine was used to block the 5-HT reuptake transporter (SERT), and the levels of mRNA for tryptophan hydroxylase 1 and SERT were determined by quantitative PCR, and SERT protein was determined by Western blot." | 1.38 | Serotonin availability in rat colon is reduced during a Western diet model of obesity. ( Bertrand, PP; Bertrand, RL; Chen, H; Howitt, L; Liu, L; Murphy, TV; Sandow, SL; Senadheera, S; Tan, KL; Tanoto, A, 2012) |
| "Because obesity can affect catecholaminergic signaling, we determined the effects of i." | 1.34 | Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. ( Billes, SK; Cowley, MA, 2007) |
| "Leptin is a permissive metabolic signal for reproduction, but GnRH neurons do not appear to express leptin receptors, suggesting that interneurons transmit leptin signals to these cells." | 1.31 | Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction? ( Clayton, AH; Howard, LC; Moenter, SM; Sullivan, SD, 2002) |
| "Obesity is one of the pathologies with ever-increasing prevalence in modern societies." | 1.31 | [The role of pharmacotherapy for treatment of obesity in adults]. ( Czupryniak, L; Drzewoski, J, 2000) |
| "Hypogonadotropic hypogonadism is a major characteristic of patients with PWS, and it is speculated to be due to hypothalamic insufficiency." | 1.29 | Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. ( Clayton, AH; O'Donnell, T; Shaw, HA; Warnock, JK, 1995) |
| "Fluoxetine treatment of mice restricted to 3." | 1.28 | Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice. ( Dubuc, PU; Peterson, CM, 1990) |
| " The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated." | 1.27 | Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (5.93) | 18.7374 |
| 1990's | 58 (49.15) | 18.2507 |
| 2000's | 38 (32.20) | 29.6817 |
| 2010's | 12 (10.17) | 24.3611 |
| 2020's | 3 (2.54) | 2.80 |
| Authors | Studies |
|---|---|
| Serralde-Zuñiga, AE | 1 |
| González-Garay, AG | 1 |
| Rodríguez-Carmona, Y | 1 |
| Meléndez-Mier, G | 1 |
| Ganesh, D | 1 |
| Chiang, JN | 1 |
| Corradetti, G | 1 |
| Zaitlen, N | 1 |
| Halperin, E | 1 |
| Sadda, SR | 1 |
| Choi, YJ | 1 |
| Choi, CY | 1 |
| Kim, CU | 1 |
| Shin, S | 1 |
| Scabia, G | 1 |
| Barone, I | 1 |
| Mainardi, M | 1 |
| Ceccarini, G | 1 |
| Scali, M | 1 |
| Buzzigoli, E | 1 |
| Dattilo, A | 1 |
| Vitti, P | 1 |
| Gastaldelli, A | 1 |
| Santini, F | 1 |
| Pizzorusso, T | 1 |
| Maffei, L | 1 |
| Maffei, M | 1 |
| da Silva, AI | 1 |
| Braz, GRF | 1 |
| Silva, SCA | 1 |
| Pedroza, AADS | 1 |
| de Lima-Júnior, NC | 1 |
| Silva, TLA | 1 |
| Lagranha, CJ | 1 |
| Lee, SH | 1 |
| Mastronardi, CA | 1 |
| Li, RW | 1 |
| Paz-Filho, G | 1 |
| Dutcher, EG | 1 |
| Lewis, MD | 1 |
| Vincent, AD | 1 |
| Smith, PN | 1 |
| Bornstein, SR | 1 |
| Licinio, J | 1 |
| Wong, ML | 1 |
| Boudreau, DM | 1 |
| Arterburn, D | 4 |
| Bogart, A | 1 |
| Haneuse, S | 1 |
| Theis, MK | 1 |
| Westbrook, E | 1 |
| Simon, G | 1 |
| Suplicy, H | 1 |
| Boguszewski, CL | 1 |
| dos Santos, CM | 1 |
| do Desterro de Figueiredo, M | 1 |
| Cunha, DR | 1 |
| Radominski, R | 1 |
| Lin, CH | 1 |
| Chen, CC | 1 |
| Wong, J | 1 |
| McIntyre, RS | 1 |
| France, M | 1 |
| Skorich, E | 1 |
| Kadrofske, M | 1 |
| Swain, GM | 1 |
| Galligan, JJ | 1 |
| Leombruni, P | 1 |
| Pierò, A | 1 |
| Lavagnino, L | 1 |
| Brustolin, A | 1 |
| Campisi, S | 1 |
| Fassino, S | 1 |
| Zarate, J | 4 |
| Churruca, I | 5 |
| Pascual, J | 1 |
| Casis, L | 5 |
| Sallés, J | 2 |
| Echevarría, E | 6 |
| López de Jesús, M | 1 |
| Saenz del Burgo, L | 2 |
| Downe, KA | 1 |
| Goldfein, JA | 2 |
| Devlin, MJ | 2 |
| Ayala, ME | 1 |
| Rezvanian, H | 1 |
| Hashemipour, M | 1 |
| Kelishadi, R | 1 |
| Tavakoli, N | 1 |
| Poursafa, P | 1 |
| Ariturk, Z | 1 |
| Alici, H | 1 |
| Cakici, M | 1 |
| Davutoglu, V | 1 |
| Bertrand, RL | 1 |
| Senadheera, S | 1 |
| Tanoto, A | 1 |
| Tan, KL | 1 |
| Howitt, L | 1 |
| Chen, H | 1 |
| Murphy, TV | 1 |
| Sandow, SL | 1 |
| Liu, L | 1 |
| Bertrand, PP | 1 |
| Grilo, CM | 2 |
| Crosby, RD | 1 |
| Wilson, GT | 2 |
| Masheb, RM | 2 |
| Kumar, J | 1 |
| Chuang, JC | 1 |
| Na, ES | 1 |
| Kuperman, A | 1 |
| Gillman, AG | 1 |
| Mukherjee, S | 1 |
| Zigman, JM | 1 |
| McClung, CA | 1 |
| Lutter, M | 1 |
| Werneke, U | 1 |
| Taylor, D | 1 |
| Sanders, TA | 1 |
| Epling, J | 1 |
| Weng, CS | 1 |
| Hung, YL | 1 |
| Shyu, LY | 1 |
| Chang, YH | 1 |
| Papakostas, GI | 1 |
| Petersen, T | 1 |
| Iosifescu, DV | 1 |
| Burns, AM | 1 |
| Nierenberg, AA | 1 |
| Alpert, JE | 1 |
| Rosenbaum, JF | 1 |
| Fava, M | 1 |
| Maina, G | 1 |
| Albert, U | 1 |
| Salvi, V | 1 |
| Bogetto, F | 1 |
| Shekelle, PG | 1 |
| Morton, SC | 1 |
| Maglione, M | 1 |
| Suttorp, M | 1 |
| Tu, W | 1 |
| Li, Z | 1 |
| Maggard, M | 1 |
| Mojica, WA | 1 |
| Shugarman, L | 1 |
| Solomon, V | 1 |
| Portillo, MP | 4 |
| Gutiérreza, A | 1 |
| Macarulla, MT | 4 |
| Norris, SL | 1 |
| Zhang, X | 1 |
| Avenell, A | 1 |
| Gregg, E | 1 |
| Schmid, CH | 1 |
| Lau, J | 1 |
| Compton, R | 1 |
| Spiller, HA | 1 |
| Bosse, GM | 1 |
| DeLaet, D | 1 |
| Flum, D | 1 |
| Molinari, E | 1 |
| Baruffi, M | 1 |
| Croci, M | 1 |
| Marchi, S | 1 |
| Petroni, ML | 1 |
| Goldstein, DJ | 8 |
| Rampey, AH | 6 |
| Dornseif, BE | 1 |
| Levine, LR | 4 |
| Potvin, JH | 4 |
| Fludzinski, LA | 2 |
| Roback, PJ | 3 |
| Wilson, MG | 3 |
| Visser, M | 2 |
| Seidell, JC | 2 |
| Koppeschaar, HP | 6 |
| Smits, P | 2 |
| Andersen, SW | 1 |
| Clemow, DB | 1 |
| Corya, SA | 1 |
| Zumalabe, JM | 1 |
| Billes, SK | 1 |
| Cowley, MA | 1 |
| Dastjerdi, MS | 1 |
| Kazemi, F | 1 |
| Najafian, A | 1 |
| Mohammady, M | 1 |
| Aminorroaya, A | 1 |
| Amini, M | 1 |
| Whigham, LD | 1 |
| Dhurandhar, NV | 1 |
| Rahko, PS | 1 |
| Atkinson, RL | 2 |
| Guimarães, C | 1 |
| Pereira, LR | 1 |
| Iucif Júnior, N | 1 |
| Cesarino, EJ | 1 |
| de Almeida, CA | 1 |
| de Carvalho, D | 1 |
| Queiroz, RH | 1 |
| Toubro, S | 1 |
| Carvalho, DF | 1 |
| Cercato, C | 1 |
| Almeida, MQ | 1 |
| Mancini, MC | 1 |
| Halpern, A | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Gutiérrez, A | 2 |
| Fernández-Soto, ML | 1 |
| González-Jiménez, A | 1 |
| Barredo-Acedo, F | 1 |
| Luna del Castillo, JD | 1 |
| Escobar-Jiménez, F | 1 |
| Mendoza Espejo, R | 1 |
| Díaz Pérez de Madrid, J | 1 |
| Buitrago, F | 1 |
| Warnock, JK | 1 |
| Clayton, AH | 2 |
| Shaw, HA | 1 |
| O'Donnell, T | 1 |
| Spring, B | 1 |
| Wurtman, J | 1 |
| Wurtman, R | 1 |
| el-Khoury, A | 1 |
| Goldberg, H | 1 |
| McDermott, J | 1 |
| Pingitore, R | 1 |
| Barak, Y | 2 |
| Lampl, Y | 1 |
| Achiron, A | 2 |
| Sarova-Pinhas, I | 1 |
| Elizur, A | 1 |
| Connolly, VM | 1 |
| Gallagher, A | 1 |
| Kesson, CM | 1 |
| Gray, DS | 3 |
| Bross, R | 1 |
| Hoffer, LJ | 1 |
| Sayler, ME | 3 |
| Holman, SL | 1 |
| Enas, GG | 3 |
| Altamura, AC | 1 |
| Moro, AR | 1 |
| Percudani, M | 1 |
| Pijl, H | 4 |
| Cohen, AF | 1 |
| Iestra, JA | 1 |
| Schoemaker, HC | 1 |
| Frölich, M | 4 |
| Onkenhout, W | 1 |
| Meinders, AE | 7 |
| Lamberto, M | 1 |
| Novi, RF | 1 |
| Mantovan, M | 1 |
| Masica, DN | 1 |
| Beasley, CM | 2 |
| Tollefson, GD | 2 |
| Fawcett, J | 1 |
| Winokur, G | 1 |
| Faries, DE | 1 |
| Willekens, FL | 2 |
| Lawton, CL | 1 |
| Wales, JK | 1 |
| Hill, AJ | 1 |
| Blundell, JE | 1 |
| Araya, V | 1 |
| Contreras, P | 1 |
| Aguirre, C | 1 |
| Depix, MS | 1 |
| Zura, ML | 1 |
| Hamilton, SH | 1 |
| Dryden, S | 2 |
| Frankish, HM | 1 |
| Wang, Q | 1 |
| Pickavance, L | 1 |
| Williams, G | 2 |
| Greeno, CG | 1 |
| Wing, RR | 2 |
| Breum, L | 1 |
| Bjerre, U | 1 |
| Bak, JF | 1 |
| Jacobsen, S | 1 |
| Astrup, A | 1 |
| Jordaan, GP | 1 |
| Roberts, MC | 1 |
| Emsley, RA | 1 |
| Daubresse, JC | 2 |
| Kolanowski, J | 2 |
| Krzentowski, G | 2 |
| Kutnowski, M | 2 |
| Scheen, A | 2 |
| Van Gaal, L | 2 |
| Maheux, P | 1 |
| Ducros, F | 1 |
| Bourque, J | 1 |
| Garon, J | 1 |
| Chiasson, JL | 1 |
| Anchors, M | 1 |
| Weiser, M | 1 |
| Frishman, WH | 1 |
| Michaelson, MD | 1 |
| Abdeen, MA | 1 |
| Jackson, HC | 1 |
| Needham, AM | 1 |
| Hutchins, LJ | 1 |
| Mazurkiewicz, SE | 1 |
| Heal, DJ | 1 |
| Boyd, LD | 1 |
| Dwyer, JT | 1 |
| Papas, A | 1 |
| Huang, CC | 1 |
| Chian, CY | 1 |
| Lin, JD | 1 |
| Poston, WS | 1 |
| Foreyt, JP | 1 |
| Borrell, L | 1 |
| Haddock, CK | 1 |
| Mayer, LE | 1 |
| Walsh, BT | 1 |
| Noy, S | 1 |
| Pinhas-Hamiel, O | 1 |
| Cowley, G | 1 |
| Springen, K | 1 |
| Ward, AS | 1 |
| Comer, SD | 1 |
| Haney, M | 1 |
| Fischman, MW | 1 |
| Foltin, RW | 1 |
| Brown, M | 1 |
| King, P | 1 |
| Bondi, M | 1 |
| Menozzi, R | 1 |
| Bertolini, M | 1 |
| Venneri, MG | 1 |
| Del Rio, G | 1 |
| Carino, JS | 1 |
| Wolk, SL | 1 |
| Voznesenskaia, TG | 1 |
| Safonova, VA | 1 |
| Platonova, NM | 1 |
| Czupryniak, L | 1 |
| Drzewoski, J | 1 |
| Dursun, SM | 1 |
| Devarajan, S | 1 |
| Rios, M | 1 |
| Fan, G | 1 |
| Fekete, C | 1 |
| Kelly, J | 1 |
| Bates, B | 1 |
| Kuehn, R | 1 |
| Lechan, RM | 1 |
| Jaenisch, R | 1 |
| Sullivan, SD | 1 |
| Howard, LC | 1 |
| Moenter, SM | 1 |
| Poyurovsky, M | 1 |
| Pashinian, A | 1 |
| Gil-Ad, I | 1 |
| Maayan, R | 1 |
| Schneidman, M | 1 |
| Fuchs, C | 1 |
| Weizman, A | 1 |
| Saracíbar, G | 1 |
| Rodríguez, VM | 1 |
| Abecia, LC | 1 |
| Potter van Loon, BJ | 2 |
| Radder, JK | 2 |
| Krans, HM | 2 |
| Zwinderman, AH | 2 |
| Fujioka, K | 2 |
| Devine, W | 2 |
| Bray, GA | 2 |
| Stinson, JC | 1 |
| Murphy, CM | 1 |
| Andrews, JF | 1 |
| Tomkin, GH | 1 |
| Kopelman, PG | 1 |
| Elliott, MW | 1 |
| Simonds, A | 1 |
| Cramer, D | 1 |
| Ward, S | 1 |
| Wedzicha, JA | 1 |
| Friedman, H | 1 |
| Op de Kamp, I | 1 |
| Veldhuis, HD | 1 |
| Wise, SD | 1 |
| Munro, JF | 1 |
| Scott, C | 1 |
| Hodge, J | 1 |
| Darga, LL | 1 |
| Carroll-Michals, L | 1 |
| Botsford, SJ | 1 |
| Lucas, CP | 2 |
| Zelissen, PM | 1 |
| Dubuc, PU | 1 |
| Peterson, CM | 1 |
| Marcus, MD | 1 |
| Ewing, L | 1 |
| Kern, E | 1 |
| McDermott, M | 1 |
| Gooding, W | 1 |
| Thompson, WL | 1 |
| Byyny, RL | 1 |
| Dauer, AD | 1 |
| Kirby, RW | 1 |
| Kreindler, TG | 1 |
| Levy, B | 1 |
| McIlwain, HH | 1 |
| Kinney-Parker, JL | 1 |
| Smith, D | 1 |
| Ingle, SF | 1 |
| Ferguson, JM | 2 |
| Feighner, JP | 1 |
| Rosenblatt, S | 1 |
| Bosomworth, J | 1 |
| Zerbe, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Do Visuals of Symptom Change Increase Rates of Rapid Response in First Weeks of CBT for Eating Disorders?[NCT02940613] | 80 participants (Anticipated) | Interventional | 2016-12-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for fluoxetine and Obesity
| Article | Year |
|---|---|
Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review.
Topics: Adult; Body Mass Index; Fluoxetine; Humans; Obesity; Overweight; Systematic Reviews as Topic | 2022 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; | 2002 |
Pharmacological and surgical treatment of obesity.
Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric | 2004 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O | 2003 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O | 2004 |
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetin | 2005 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty; | 2005 |
[Therapeutical approach of obesity in Prader-Willi Syndrome].
Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Child; Child, Preschool; Female; Fluoxetine; Fru | 2007 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Clinical pharmacokinetics of fluoxetine.
Topics: Administration, Oral; Aged; Aging; Biological Availability; Dose-Response Relationship, Drug; Drug I | 1994 |
Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
Topics: Antidepressive Agents, Tricyclic; Bulimia; Clinical Trials as Topic; Depressive Disorder; Double-Bli | 1993 |
Adverse event frequencies generate hypotheses of efficacy and safety.
Topics: Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Humans; Obesity; Placebos; Randomized C | 1993 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo | 1997 |
Challenges in obesity management.
Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobu | 1998 |
The use of selective serotonin reuptake inhibitors in eating disorders.
Topics: Anorexia Nervosa; Antidepressive Agents; Bulimia; Clinical Trials as Topic; Combined Modality Therap | 1998 |
Clinical studies with fluoxetine in obesity.
Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Weight Loss | 1992 |
Appraisal of the clinical value of serotoninergic drugs.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Obesity; Serotonin; Weight Loss | 1992 |
Very low calorie diets and recently developed anti-obesity drugs for treating overweight in non-insulin-dependent diabetics.
Topics: Adrenergic beta-Agonists; Diabetes Mellitus, Type 2; Diet, Reducing; Fenfluramine; Fluoxetine; Human | 1990 |
[Regulation of food intake and the treatment of obesity using centrally-active serotonergic drugs].
Topics: Adult; Energy Intake; Energy Metabolism; Female; Fenfluramine; Fluoxetine; Humans; Male; Middle Aged | 1991 |
Fluoxetine and weight: something lost and something gained?
Topics: Appetite; Fluoxetine; Humans; Obesity | 1989 |
51 trials available for fluoxetine and Obesity
| Article | Year |
|---|---|
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die | 2014 |
A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder.
Topics: Adult; Body Mass Index; Bulimia Nervosa; Double-Blind Method; Female; Fluoxetine; Humans; Middle Age | 2008 |
Restraint, hunger, and disinhibition following treatment for binge-eating disorder.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Body Mass Index; Bulimia Nervosa; Cognitive B | 2009 |
A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity.
Topics: Adolescent; Child; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metformin; Obesity | 2010 |
12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder.
Topics: Adolescent; Adult; Binge-Eating Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; D | 2012 |
Obesity among outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depr | 2005 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies | 2004 |
Binge eating disorder in obesity: comparison of different therapeutic strategies.
Topics: Adult; Aged; Body Mass Index; Bulimia Nervosa; Cognitive Behavioral Therapy; Cohort Studies; Combine | 2005 |
Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Carbohydrates; Cholesterol; Cholesterol, LDL; | 1993 |
No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity.
Topics: Abdominal Fat; Adult; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Weight; Double-Blind | 1994 |
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Depressive Disorder, | 2005 |
Rapid response to treatment for binge eating disorder.
Topics: Adolescent; Adult; Bulimia Nervosa; Cognitive Behavioral Therapy; Double-Blind Method; Female; Fluox | 2006 |
An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Drug Therapy, Combination; Female; | 2007 |
Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Appetite Depressa | 2006 |
Comparison of fluoxetine and placebo in the treatment of obesity.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Fluoxetine; Humans; Obesity; Selective Serot | 1995 |
[Effectiveness of serotonergic agonists in the treatment of obese patients].
Topics: Adult; Appetite Depressants; Body Mass Index; Diet, Reducing; Female; Fenfluramine; Fluoxetine; Foll | 1995 |
Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Dietary Carbohydrates; Dietary P | 1995 |
A study of fluoxetine in obese elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Evaluation S | 1995 |
Fluoxetine increases resting energy expenditure and basal body temperature in humans.
Topics: Adult; Body Temperature; Chemotherapy, Adjuvant; Diet, Reducing; Double-Blind Method; Energy Metabol | 1995 |
Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Female; Flu | 1994 |
Pattern analysis method for assessing successful weight reduction.
Topics: Adult; Aged; Blood Pressure; Confidence Intervals; Counseling; Diabetes Mellitus, Type 2; Double-Bli | 1994 |
Fluoxetine: a randomized clinical trial in the treatment of obesity.
Topics: Adult; Body Mass Index; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; | 1994 |
Evidence for brain serotonin-mediated control of carbohydrate consumption in normal weight and obese humans.
Topics: Adult; Amino Acids; Analysis of Variance; Appetite Regulation; Blood Glucose; Brain; Diet; Dietary C | 1993 |
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Benzphetamine; Body Mass Index; Comorbidity; Depressive Di | 1993 |
The effect of fluoxetine on body weight, body composition and visceral fat accumulation.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Double-Blind Method; Fluoxetine; Humans; Magnetic | 1993 |
Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects.
Topics: Adult; Body Weight; Cross-Over Studies; Dietary Carbohydrates; Dietary Fats; Double-Blind Method; Ea | 1995 |
Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success.
Topics: Double-Blind Method; Fluoxetine; Humans; Obesity; Placebos; Risk Factors; Selective Serotonin Reupta | 1995 |
A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder.
Topics: Adult; Affect; Appetite; Double-Blind Method; Energy Intake; Feeding and Eating Disorders; Female; F | 1996 |
Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
Topics: Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Fluoxetine; Glucose Intol | 1995 |
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dou | 1996 |
Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine | 1997 |
Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet.
Topics: Adult; Diet, Reducing; Energy Intake; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Select | 1998 |
Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Body Mass Index; Female; | 1999 |
Fluoxetine-maintained obese humans: effect on food intake and body weight.
Topics: Adult; Affect; Analysis of Variance; Body Weight; Eating; Female; Fluoxetine; Humans; Male; Obesity; | 1999 |
Metabolic effects of fluoxetine in obese menopausal women.
Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Body Temperature Regulation; Double-Blind M | 2000 |
Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy.
Topics: Adult; Appetite Depressants; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, | 2000 |
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Co | 2002 |
Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine; Glucose; Humans; Insu | 1992 |
Fluoxetine treatment of the obese diabetic.
Topics: Adult; Blood Glucose; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blin | 1992 |
An assessment of the thermogenic effects of fluoxetine in obese subjects.
Topics: Adult; Basal Metabolism; Body Temperature Regulation; Double-Blind Method; Female; Fluoxetine; Human | 1992 |
Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation.
Topics: Adult; Apnea; Double-Blind Method; Female; Fluoxetine; Humans; Hypoventilation; Male; Middle Aged; O | 1992 |
Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose; Glu | 1992 |
A randomized double-blind clinical trial of fluoxetine in obese diabetics.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Femal | 1992 |
Fluoxetine therapy in obese diabetic and glucose intolerant patients.
Topics: Blood Glucose; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose Tolerance Test; G | 1992 |
Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity.
Topics: Adult; Body Mass Index; Body Weight; Brain; Energy Intake; Female; Fluoxetine; Food Preferences; Hum | 1991 |
Clinical studies with fluoxetine in obesity.
Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Weight Loss | 1992 |
Fluoxetine's effect on weight loss in obese subjects.
Topics: Adolescent; Adult; Double-Blind Method; Fluoxetine; Humans; Middle Aged; Obesity; Time Factors; Weig | 1991 |
A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters.
Topics: Adolescent; Adult; Attitude to Health; Behavior Therapy; Bulimia; Clinical Trials as Topic; Combined | 1990 |
Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Middle | 1989 |
Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity.
Topics: Adolescent; Adult; Aged; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Propylamines | 1987 |
Fluoxetine-induced weight loss in overweight, nondepressed subjects.
Topics: Adolescent; Adult; Aged; Appetite; Body Weight; Clinical Trials as Topic; Double-Blind Method; Femal | 1986 |
48 other studies available for fluoxetine and Obesity
| Article | Year |
|---|---|
Effect of statins on the age of onset of age-related macular degeneration.
Topics: Age of Onset; Female; Fluoxetine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular De | 2023 |
A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Fluoxetine; Humans; Male; Obesity; Pharmac | 2023 |
The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF.
Topics: Adipose Tissue, White; Animals; Antidepressive Agents; Body Weight; Brain-Derived Neurotrophic Facto | 2018 |
Body composition, biochemical, behavioral and molecular alterations in overfed rats after chronic exposure to SSRI.
Topics: Animals; Behavior, Animal; Body Composition; Body Weight; Eating; Energy Metabolism; Fluoxetine; Hyp | 2019 |
Short-term antidepressant treatment has long-lasting effects, and reverses stress-induced decreases in bone features in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bone Density; Disease Models, Animal; Fluoxetine; | 2019 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; De | 2013 |
Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depressive Disorder, | 2014 |
Sex-related differences in small intestinal transit and serotonin dynamics in high-fat-diet-induced obesity in mice.
Topics: Animals; Carbolines; Diet, High-Fat; Female; Fluoxetine; Gastrointestinal Transit; Intestine, Small; | 2016 |
Brain endocannabinoid system is involved in fluoxetine-induced anorexia.
Topics: Animals; Anorexia; Brain; Brain Chemistry; Cannabinoid Receptor Modulators; Corpus Striatum; Endocan | 2008 |
Immunohistochemical localization of CB1 cannabinoid receptors in frontal cortex and related limbic areas in obese Zucker rats: effects of chronic fluoxetine treatment.
Topics: Analysis of Variance; Animals; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; | 2008 |
Brain serotonin, psychoactive drugs, and effects on reproduction.
Topics: Affect; Amphetamine-Related Disorders; Animals; Biological Clocks; Brain; Cognition Disorders; Depre | 2009 |
A rare cause of syncope: cough.
Topics: Antidepressive Agents, Second-Generation; Cough; Fluoxetine; Gastroesophageal Reflux; Humans; Male; | 2012 |
Serotonin availability in rat colon is reduced during a Western diet model of obesity.
Topics: Animals; Colon; Constipation; Diet; Diet, High-Fat; Enterochromaffin Cells; Fluoxetine; Gastrointest | 2012 |
Differential effects of chronic social stress and fluoxetine on meal patterns in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Corticosterone; Eating; Energy I | 2013 |
Is fluoxetine an effective therapy for weight loss in obese patients?
Topics: Fluoxetine; Humans; Obesity; Selective Serotonin Reuptake Inhibitors | 2003 |
A study of electrical conductance of meridian in the obese during weight reduction.
Topics: Adult; Body Mass Index; Case-Control Studies; Diet, Reducing; Electric Impedance; Exercise; Female; | 2004 |
Effects of fluoxetine administration on regional galanin expression in obese Zucker rat hypothalamus.
Topics: Adipose Tissue; Animals; Body Composition; Body Weight; Eating; Fluoxetine; Galanin; Hypothalamus; M | 2004 |
Fatal fluoxetine ingestion with postmortem blood concentrations.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Bradycardia; Child, Preschool; Dia | 2005 |
Baseline predictors of success when comparing two treatments.
Topics: Anti-Obesity Agents; Fluoxetine; Humans; Obesity; Predictive Value of Tests; Randomized Controlled T | 1994 |
Fluoxetine alters mu opioid receptor expression in obese Zucker rat extrahypothalamic regions.
Topics: Animals; Brain; Cell Count; Disease Models, Animal; Fluoxetine; Gene Expression; Immunohistochemistr | 2006 |
Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
Topics: Animals; Behavior, Animal; Body Weight; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drug | 2007 |
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
Topics: Adult; Appetite Depressants; Body Mass Index; Drug Therapy, Combination; Fenfluramine; Fluoxetine; H | 2007 |
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based M | 2007 |
Effects of fluoxetine administration on hypothalamic melanocortin system in obese Zucker rats.
Topics: Agouti-Related Protein; alpha-MSH; Animals; Appetite Depressants; Body Weight; DNA Primers; Eating; | 2008 |
Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine.
Topics: Adult; Age of Onset; Female; Fluoxetine; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; | 1995 |
Fluoxetine induced weight loss: a pilot study in postpartum women.
Topics: Adult; Female; Fluoxetine; Humans; Obesity; Pilot Projects; Puerperal Disorders; Weight Loss | 1995 |
Response to Roback et al.
Topics: Adolescent; Adult; Fluoxetine; Humans; Obesity; Weight Loss | 1995 |
Fluoxetine (Prozac) and other drugs for treatment of obesity.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Fenfluramine; Fluoxetine; Humans; Obesity; Phen | 1994 |
[Fluoxetine and obesity].
Topics: Adolescent; Appetite; Combined Modality Therapy; Fluoxetine; Humans; Male; Obesity; Serotonin | 1993 |
The influence of serotonergic neurotransmission on pituitary hormone release in obese and non-obese females.
Topics: Adrenocorticotropic Hormone; Adult; Analysis of Variance; beta-Endorphin; Corticotropin-Releasing Ho | 1993 |
[The effect of fluoxetine on insulin resistance in non diabetic obese patients].
Topics: Adult; Antidepressive Agents, Second-Generation; Fluoxetine; Glucose Tolerance Test; Humans; Insulin | 1995 |
The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Autoradiography; Blood Glucose; Body Weight; Eating; Fluox | 1996 |
Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report.
Topics: Adult; Body Weight; Brain Damage, Chronic; Dose-Response Relationship, Drug; Fenfluramine; Fluoxetin | 1996 |
Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Hypertension, Pulmonary; Obesity; Selective | 1997 |
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptak | 1997 |
Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study.
Topics: Adult; Antidepressive Agents; Dental Caries; Diet; Female; Fenfluramine; Fluoxetine; Humans; Obesity | 1997 |
After fen-phen.
Topics: Antidepressive Agents, Second-Generation; Appetite Depressants; Consumer Product Safety; Fenfluramin | 1997 |
Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine.
Topics: Animals; Eating; Fluoxetine; Leptin; Male; Obesity; Proteins; Rats; Rats, Zucker; Selective Serotoni | 1999 |
[Disorder of eating behavior and comorbid syndromes in obesity and methods of their correction].
Topics: Adult; Depressive Disorder; Feeding Behavior; Female; Fluoxetine; Humans; Obesity; Selective Seroton | 2000 |
[The role of pharmacotherapy for treatment of obesity in adults].
Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agoni | 2000 |
Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?
Topics: Adult; Antidepressive Agents, Second-Generation; Appetite; Depressive Disorder; Drug Therapy, Combin | 2001 |
Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity.
Topics: Animals; Anxiety; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Fasting; Fluoxetine; Gene D | 2001 |
Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction?
Topics: Animals; Body Weight; Diabetes Mellitus; Eating; Estrous Cycle; Fasting; Female; Fertility; Fluoxeti | 2002 |
Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Composition; Body Weight; Carrier Proteins; | 2002 |
Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice.
Topics: Animals; Body Composition; Body Weight; Drug Administration Schedule; Eating; Female; Fluoxetine; In | 1990 |
Fluoxetine for depression.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Humans; Obesity; Obsessive-Compul | 1988 |
Fluoxetine-induced weight loss in overweight non-depressed humans.
Topics: Adolescent; Adult; Depressive Disorder; Dietary Carbohydrates; Female; Fluoxetine; Humans; Male; Mid | 1987 |
Safety of fluoxetine in the treatment of obesity.
Topics: Drug Interactions; Fluoxetine; Heart; Humans; Lipidoses; Liver; Obesity; Phospholipids; Propylamines | 1987 |